Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iFOCUS: HIFU-HT and ICI in Metastatic or Unresectable Cancer
NCT06524570Phase 1Recruiting
- Start
- Jul 2024
- Primary completion
- Aug 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab and nivolumab in metastatic cancer. Primary endpoints: Adverse Events, Discontinuation Rate up to 2 years and 6 more. Started Jul 2024; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT06524570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06524570.